Methylprednisolone reduced auto-immune platelet destruction while romiplostim, a thrombopoietin receptor agonist, was still used to stimulate platelet production as per ITP treatment protocols [11]. This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.